Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Viewpoint
  • Published:

Rituximab for membranous nephropathy and immune disease: less might be enough

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Remuzzi G et al. (2002) Rituximab for idiopathic membranous nephropathy. Lancet 360: 923–924

    Article  CAS  PubMed  Google Scholar 

  2. Ruggenenti P et al. (2003) Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 14: 1851–1857

    Article  CAS  PubMed  Google Scholar 

  3. Fervenza FC et al. (2008) Rituximab treatment for idiopathic membranous nephropathy. Kidney Int 73: 117–125

    Article  CAS  PubMed  Google Scholar 

  4. Perna A et al. (2004) Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 44: 385–401

    Article  PubMed  Google Scholar 

  5. Salama AD and Pusey CD (2006) Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2: 221–230

    Article  CAS  PubMed  Google Scholar 

  6. Looney RJ et al. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50: 2580–2589

    Article  CAS  PubMed  Google Scholar 

  7. Cravedi P et al. (2007) Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2: 932–937

    Article  CAS  PubMed  Google Scholar 

  8. Arnold DM et al. (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146: 25–33

    Article  PubMed  Google Scholar 

  9. Albert D et al. (2008) Variability in the biological response to anti-CD20 B-cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 67: 1724–1731

    Article  CAS  PubMed  Google Scholar 

  10. US Food and Drug Administration (online 18 December 2006) 2006 Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements [http://www.fda.gov/medwatch/safety/2006/safety06.htm#rituxan] (accessed 21 October 2008)

  11. Fairweather H et al. (2008) Abbreviated dose rituximab for immune-mediated hematological disorders. Am J Hematol 83: 554–557

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Giuseppe Remuzzi.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ruggenenti, P., Cravedi, P. & Remuzzi, G. Rituximab for membranous nephropathy and immune disease: less might be enough. Nat Rev Nephrol 5, 76–77 (2009). https://doi.org/10.1038/ncpneph1007

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph1007

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing